Non-suppression of cortisol secretion by long term treatment with ketoconazole in patients with acute leukaemia.
Open Access
- 1 June 1985
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 38 (6) , 677-678
- https://doi.org/10.1136/jcp.38.6.677
Abstract
Ketoconazole, a potent antifungal agent, inhibits adrenal steroidogenesis in normal subjects during short term treatment. Since this drug is used in the long term prophylaxis of fungal infections in patients with haematological malignancies, we have investigated whether such patients have evidence of adrenocortical suppression. Six patients on long term prophylaxis with ketoconazole were given tetracosactrin stimulation tests. All patients had high basal cortisol concentrations, which increased further after administration of 25 IU of tetracosactrin. It is concluded that leukaemic patients receiving long term ketoconazole treatment do not have adrenocortical suppression. They may, in fact, have hyperstimulated adrenocortical function due to stress and hypovolaemia.This publication has 7 references indexed in Scilit:
- Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.BMJ, 1983
- The pharmacokinetics of ketoconazole in severely immunocompromised patientsJournal of Antimicrobial Chemotherapy, 1982
- Ketoconazole Blocks Adrenal Steroid SynthesisAnnals of Internal Medicine, 1982
- Ketoconazole.BMJ, 1982
- KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTSThe Lancet, 1982